1. Home
  2. PSQH vs GLTO Comparison

PSQH vs GLTO Comparison

Compare PSQH & GLTO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo PSQ Holdings Inc.

PSQH

PSQ Holdings Inc.

HOLD

Current Price

$0.77

Market Cap

52.7M

ML Signal

HOLD

Logo Galecto Inc.

GLTO

Galecto Inc.

HOLD

Current Price

$30.50

Market Cap

54.5M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
PSQH
GLTO
Founded
2021
2011
Country
United States
Denmark
Employees
N/A
N/A
Industry
Advertising
Biotechnology: Pharmaceutical Preparations
Sector
Consumer Discretionary
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
52.7M
54.5M
IPO Year
N/A
2020

Fundamental Metrics

Financial Performance
Metric
PSQH
GLTO
Price
$0.77
$30.50
Analyst Decision
Strong Buy
Strong Buy
Analyst Count
1
2
Target Price
$4.00
$41.00
AVG Volume (30 Days)
3.4M
248.6K
Earning Date
03-12-2026
03-18-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
$27,534,522.00
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
$45.49
N/A
P/E Ratio
N/A
N/A
Revenue Growth
196.08
N/A
52 Week Low
$0.62
$2.01
52 Week High
$3.97
$38.33

Technical Indicators

Market Signals
Indicator
PSQH
GLTO
Relative Strength Index (RSI) 33.29 57.99
Support Level $0.70 $19.85
Resistance Level $0.80 $30.03
Average True Range (ATR) 0.07 2.93
MACD 0.00 0.26
Stochastic Oscillator 30.04 90.32

Price Performance

Historical Comparison
PSQH
GLTO

About PSQH PSQ Holdings Inc.

PSQ Holdings Inc operates the website and mobile application named as PublicSq. It is an app and website that connects freedom-loving Americans to high-quality businesses that share values, both online and in local communities. It has three reportable segments comprised of Marketplace; which includes a marketplace platform to access consumers that are drawn to patriotic values and the revenue is generated in the form of advertising and eCommerce transactions, and Brands segment in which through its wholly-owned brand, the company generates revenue from online sales of diapers and wipes and third financial technology which assists consumers, lenders, and retailers in offering point-of-sale financing products.

About GLTO Galecto Inc.

Galecto Inc is a clinical-stage biotechnology company developing therapeutics designed to target the biological processes that lie at the heart of cancer and liver diseases. Its initial focus is on the development of small-molecule inhibitors of galectin-3 and lysyl oxidase-like 2, or LOXL2. Its product candidate GB0139 is for the treatment of severe fibrotic lung diseases such as idiopathic pulmonary fibrosis, or IPF, a life-threatening progressive fibrotic disease of the lung. Its product GB1211, a selective oral galectin-3 inhibitor for the treatment of fibrosis related to non-alcoholic steatohepatitis, or NASH, and GB2064, a selective oral inhibitor of LOXL2 that it initially plans to develop for the treatment of myelofibrosis.

Share on Social Networks: